April 14th 2025
An increase in protocol complexity is paving the way for machine learning models to optimize trial design.
December 20th 2024
Potential Pitfalls Without RBQM Adoption
May 16th 2024In part 4 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints touch on what risks companies leave themselves susceptible to without the adoption of risk-based approaches.
Increasing Comfortability With Adopting Risk-Based Approaches
May 14th 2024In part 3 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management.
Ken Getz of Tufts CSDD Discusses RBQM Study Conducted with CluePoints and PwC
May 10th 2024In part 1 of this video interview series with Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints, Getz touches on the findings from a recent study on RBQM adoption.
Industry Assessment of Risk-Based Quality Management Emphasizes Value of Adoption
April 4th 2024A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.